ライフサイエンスコーパス: lipogenic

1 by the gut microbiota(9), and this supplies lipogenic acetyl-CoA independently of ACLY(10).

2 The pro-lipogenic action of LPA is mediated through LPA(2), an L

3 s and human skin organ culture inhibited the lipogenic actions of various compounds, including arachi

4 By this method, we revealed changes in the lipogenic activity and LD sizes during glucose starvatio

5 FOXO-dependent glucose production devoid of lipogenic activity in hepatocytes.

6 To elucidate the molecular basis of anti-lipogenic activity of LCB, the expression of several gen

7 acid cycle, coupled with increased ketogenic/lipogenic activity via acetyl-CoA, 3-hydroybutyrate, and

8 ment of LDs reflected variations in cellular lipogenic activity, and changes in the average speed of

9 r for unsaturated fatty acids that regulates lipogenic activity.

10 had activated microglia and up-regulation of lipogenic and cholesterogenic genes, likely adaptations

11 White adipose tissue (WAT) is not only a lipogenic and fat storage tissue but also an important e

12 acetylation, as well as the induction of the lipogenic and fibrogenic proteins, are completely blocke

13 in healthy flies and promotes expression of lipogenic and glycogenic enzymes.

14 of gene expression with increased levels of lipogenic and glycolytic enzymes.

15 n as MLXIPL), a transcriptional regulator of lipogenic and glycolytic genes.

16 In contrast, the ability of MR to regulate lipogenic and integrated stress response genes in liver

17 Consistent with these findings, lipogenic and lipid uptake genes were downregulated and

18 (WAT) involved a depot-specific induction of lipogenic and oxidative genes and a commensurate increas

19 c lipidosis partly through downregulation of lipogenic and/or upregulation of beta-oxidation transcri

20 These gluconeogenic, lipogenic, and inflammatory pathway transcripts were sim

21 PNPLA3 may function primarily in a lipogenic capacity and inhibition of PNPLA3 may be a nov

22 Cancer cells have enhanced lipogenic capacity characterized by increased synthesis

23 d increased in adipose tissue, where de novo lipogenic capacity is concomitantly enhanced.

24 Fructose is a lipogenic carbohydrate that contributes to insulin resis

25 RH-1 promotes the development of NAFLD under lipogenic conditions through regulation of OSBPL3.

26 fragmentation and fusion under lipolytic and lipogenic conditions, respectively.

27 thway under Western HFHC dietary and de novo lipogenic conditions.

28 ng that the enzyme is highly regulated under lipogenic conditions.

29 found in Acc2(-/-) mutant mice under de novo lipogenic conditions.

30 deliver SNAP-23 to the SNARE complexes under lipogenic conditions.

31 Akt activity, leading to a self-perpetuating lipogenic cycle.

32 Among the up-regulated genes are the anti-lipogenic deacetylase sirtuin 1 (Sirt1) and the anti-lip

33 These lipogenic defects are consistent with the down-regulatio

34 thesis, as overexpression of SREBP-1 rescues lipogenic defects associated with OGT suppression, and t

35 In response to a high-sucrose lipogenic diet, G0S2 is up-regulated via LXRalpha and re

36 osis, obesity and insulin resistance under a lipogenic diet.

37 metabolism stemming from high adiposity and lipogenic diets.

38 tes metabolic disorders, and the severity of lipogenic disease depends upon the infecting virus genot

39 Fructose is considered lipogenic due to its ability to generate triglycerides a

40 Because GIP has antilipolytic and lipogenic effects in adipocytes, the increased GIP-R exp

41 Notably, CRTC1 also mediates anti-lipogenic effects of bile acid signaling, whereas it is

42 portant role for C/EBPalpha in mediating the lipogenic effects of hepatic Trib1 deletion and provide

43 on, alleviates both anti-adipogenic and anti-lipogenic effects of Hh in cell culture models.

44 hat insulin is required specifically for the lipogenic effects of LXRalpha and that manipulation of t

45 ar whether PNPLA3 functions as a lipase or a lipogenic enzyme and whether PNPLA3 is involved in the p

46 Fatty acid synthase (FASN) is a key lipogenic enzyme catalyzing the terminal steps in the de

47 tent concomitant with increased Nrf2 and pro-lipogenic enzyme expression at W5 and W39 in female offs

48 ivating SREBP-1, which subsequently enhanced lipogenic enzyme expression.

49 Unexpectedly, the lipogenic enzyme fatty acid synthase (FAS) was increased

50 leads to repression of LXR-mediated hepatic lipogenic enzyme gene expression.

51 The increase in lipogenic enzyme levels was accompanied by up-regulation

52 is a lineage-restricted activator of the key lipogenic enzyme stearoyl-CoA desaturase (SCD) and that

53 in plasma, reflecting a high activity of the lipogenic enzyme stearoyl-CoA desaturase-1 (SCD-1), has

54 earoyl CoA desaturase 1 (SCD1) is a critical lipogenic enzyme that catalyzes the synthesis of two mon

55 Fatty acid synthase (FASN) is a lipogenic enzyme that is highly expressed in different h

56 In addition to lipogenic enzymes (Acc, Fasn, Scd1), the expression of t

57 e and protein expression measurements of key lipogenic enzymes [acetyl CoA carboxylase 1 (ACC1), fatt

58 Targeted inhibition of lipogenic enzymes abolished expression of CD44, a transm

59 Significant up-regulation of lipogenic enzymes and an elevation in hepatic peroxisome

60 ng to up-regulation of several rate-limiting lipogenic enzymes and fibrogenic factors.

61 In addition, inhibition of lipogenic enzymes and reduced expression of CD44 attenua

62 The changes in these key lipogenic enzymes are critical for the development and m

63 that impair gluconeogenic enzymes and spare lipogenic enzymes in diet-induced obesity (DIO) are obsc

64 duction of lipogenesis and expression of key lipogenic enzymes in human fibroblasts occurs by 24 h po

65 etion upregulates liver lipid deposition and lipogenic enzymes in the mouse model.

66 e translational activation of mRNAs encoding lipogenic enzymes late in the cell cycle including Acc1p

67 cribed, the impact of aberrant activation of lipogenic enzymes on cancer progression remains unknown.

68 L induction provides the substrate for these lipogenic enzymes to drive de novo lipogenesis leading t

69 ated with tumor expression of glycolytic and lipogenic enzymes, glucose uptake, and proliferation mar

70 ves coordinate transcriptional activation of lipogenic enzymes, including fatty acid synthase and gly

71 turn, SREBP1 regulates the expression of key lipogenic enzymes, including stearoyl CoA desaturase 1 (

72 decreased levels of de novo lipogenesis and lipogenic enzymes, supporting the notion that BMAL1 regu

73 sive expression of hepatic gluconeogenic and lipogenic enzymes.

74 sufficient to elevate the levels of mRNA of lipogenic enzymes.

75 (AMPK) activity, and increased expression of lipogenic enzymes.

76 and reduced expression of gluconeogenic and lipogenic enzymes.

77 ulating the expression of genes encoding key lipogenic enzymes.

78 ssociated with a decreased expression of key lipogenic enzymes/mediators, and improved glucose metabo

79 f lipid accumulation in NSPCs and subsequent lipogenic ER stress.

80 ac UCP3 expression through activation of the lipogenic factor SREBP-1.

81 neration of oxysterol ligands for LXR, a key lipogenic factor.

82 s in liver, which was associated with higher lipogenic factors Ppargamma, Lxr, Fasn, Scd1, and CD36.

83 uated these stimulating effects of orexin on lipogenic factors.

84 An excessive lipogenic flux due to chronic dietary stimulation contri

85 by PGC1alpha, thus linking the oxidative and lipogenic functions of PGC1alpha.

86 nd subsequent acetylation in insulin-induced lipogenic gene activation.

87 ly inhibits lipid accumulation by preventing lipogenic gene engagement, without affecting PPARgamma p

88 ur results reveal that XBP1s reduces hepatic lipogenic gene expression and improves hepatosteatosis i

89 mice in the fasted state displayed elevated lipogenic gene expression and loss of the kinase module

90 itutive activation of mTORC1 reduced hepatic lipogenic gene expression and produced hypotriglyceridem

91 document that XBP1s leads to suppression of lipogenic gene expression and reduction of hepatic trigl

92 TORC1 that is necessary for the induction of lipogenic gene expression because pharmacological or gen

93 that resveratrol was capable of blocking the lipogenic gene expression in CSCs and significantly supp

94 that resveratrol was capable of blocking the lipogenic gene expression in CSCs and significantly supp

95 twork and absence of bile acid repression of lipogenic gene expression in livers of Cyp7a1-tg mice.

96 PRIM mice featured increased lipogenic gene expression in the liver and adipose tissu

97 and acute hepatic depletion of Bmal1 reduced lipogenic gene expression in the liver upon refeeding.

98 Decreased lipogenic gene expression resulted in a significant redu

99 fatty acid oxidation, MKP-1 promotes hepatic lipogenic gene expression through PPARgamma.

100 The induction of lipogenic gene expression was attenuated in the L-S6K-KD

101 zed by decreased insulin signaling, enhanced lipogenic gene expression, and hepatosteatosis.

102 605906 did not mimic effects of metformin on lipogenic gene expression, glucose production, and AMP-a

103 atocyte-specific IMP2 deletion did not alter lipogenic gene expression, it substantially decreased th

104 ts show that LSD1 plays a role in regulating lipogenic gene expression, suggesting LSD1 as a potentia

105 and glucose homeostasis and reduced hepatic lipogenic gene expression, which was absent with the LR

106 BP) activity, histone acetylation, and gluco-lipogenic gene expression.

107 t and lipogenesis by reducing glycolytic and lipogenic gene expression.

108 deoxycholic acid (UDCA) inhibits LXR-induced lipogenic gene expression.

109 ently suppressed insulin and feeding-induced lipogenic gene expression.

110 d adipocyte size resulted from inhibition of lipogenic gene expression.

111 ipocytes, decreased food intake, and reduced lipogenic gene expression.

112 with increased beta-oxidation and decreased lipogenic gene expression.

113 o have both positive and negative effects on lipogenic gene expression.

114 E (Ad-SMILE) attenuated fat accumulation and lipogenic gene induction in the liver of T7 administered

115 onsistent with the development of steatosis, lipogenic gene induction was significantly increased in

116 The HCF-1:ChREBP complex resides at lipogenic gene promoters, where HCF-1 regulates H3K4 tri

117 JMJD1C is a specific histone demethylase for lipogenic gene transcription in liver.

118 specific chromatin remodeling component for lipogenic gene transcription in liver.

119 increased hepatic triglyceride (TG) content, lipogenic gene transcription, and de novo lipogenesis.

120 For regulation of lipogenic gene transcription, various known lipogenic tr

121 and fatty acid synthase (FASN), its effector lipogenic gene.

122 Acetate predominately activates lipogenic genes ACACA and FASN expression by increasing

123 inding protein that govern the expression of lipogenic genes also followed a nonmonotonic dose-respon

124 riptional factors that control expression of lipogenic genes and adipocyte differentiation.

125 jection further increased baseline levels of lipogenic genes and decreased the levels of oxidative ge

126 pid accumulation, along with upregulation of lipogenic genes and downregulation of genes related to f

127 This innate pathway induces lipogenic genes and enhances core-associated lipid dropl

128 on with a reduction in hepatic expression of lipogenic genes and improvement in liver insulin sensiti

129 icrosomal triglyceride transfer protein, and lipogenic genes and in part by posttranscriptional effec

130 we show that myostatin directly up-regulated lipogenic genes and increased fat accumulation in cultur

131 stimulates SREBP-1-meidated transcription of lipogenic genes and lipid production in breast cancer ce

132 ed that SREBP1 cleavage and the induction of lipogenic genes and lipid synthesis are all inhibited in

133 HDAC3 depletion in mouse liver upregulates lipogenic genes and results in severe hepatosteatosis.

134 LCN13 inhibited the expression of important lipogenic genes and stimulated the genes that promote be

135 mice had increased DNA-bound C/EBPalpha near lipogenic genes and the Trib1 gene, which itself was tra

136 ncy of SHP and DNMT3A and DNA methylation at lipogenic genes are low, with elevated gene expression.

137 In Tnmd transgenic mice, lipogenic genes are upregulated in eWAT, as is Ucp1 in b

138 r the increased expression of glycolytic and lipogenic genes as well as glucose-6-phosphatase (G6pc)

139 ator, hepatic loss of HNF6 up-regulated many lipogenic genes bound directly by HNF6.

140 ms differentially regulate the expression of lipogenic genes by modulating the association of the act

141 increase in lipid uptake, triglycerides, and lipogenic genes compared with macroH2A1.1.

142 tants can rescue hepatosteatosis and repress lipogenic genes expression in HDAC3-depleted mouse liver

143 , insulin sensitivity, and the expression of lipogenic genes in abdominal subcutaneous adipose and li

144 Expression levels of adipogenic and lipogenic genes in adipose tissues were also dramaticall

145 We examined the expression profile of key lipogenic genes in clinical samples of ductal carcinoma

146 es in brown adipose tissue and oxidative and lipogenic genes in inguinal WAT.

147 alpha, and LXRalpha was unable to induce the lipogenic genes in the absence of insulin.

148 Thus, insulin was unable to induce the lipogenic genes in the absence of Lxralpha, and LXRalpha

149 tor PPARdelta controls diurnal expression of lipogenic genes in the dark/feeding cycle.

150 s are consistent with the down-regulation of lipogenic genes in the KO mice.

151 riacylglycerol levels and the mRNA levels of lipogenic genes in the liver and skeletal muscle.

152 iet produced a coordinated downregulation of lipogenic genes in the liver, resulting in a correspondi

153 LPI increased the expression of lipogenic genes in visceral adipose tissue explants and

154 limit diet-induced weight gain and suppress lipogenic genes in WAT, indicating that RSL1 balances me

155 n were associated with reduced expression of lipogenic genes including Cebpa, Acc1 and Scd1.

156 r circadian clock, up-regulate expression of lipogenic genes only under fed conditions at Zeitgeber t

157 eal that most of the SHP cistrome, including lipogenic genes repressed by FGF19, have overlapping CpG

158 of ABCA1, while poorly or not activating the lipogenic genes SREBP1 and SCD1 or FASN, respectively.

159 C/EBPbeta-RNAi normalized lipogenic genes sterol regulatory element-binding protei

160 mmasome is required for the up-regulation of lipogenic genes such as 3-hydroxy-3-methylglutaryl-coenz

161 nificantly higher level of expression of all lipogenic genes than the counterpart population from non

162 tes lipogenesis by activating glycolytic and lipogenic genes through the Mondo/ChREBP-Mlx transcripti

163 Hepatic expression of key glycolytic and lipogenic genes was higher in HFD-fed TG and lower in KO

164 ds, whereas the expression of glycolytic and lipogenic genes was reduced.

165 early mouse pregnancy, expression of hepatic lipogenic genes was up-regulated and uncoupled from the

166 dipose tissue expression of inflammatory and lipogenic genes were determined.

167 ed expression of stress-related proteins and lipogenic genes were dramatically reduced.

168 Among the shared genes, more lipogenic genes were induced upon feeding in BABL/cJ tha

169 However, lipogenic genes were not differentially expressed in the

170 ion in lipid synthesis and the expression of lipogenic genes without a corresponding reduction in the

171 ession of ERK1/2 increased the expression of lipogenic genes, and orexin treatment induced the phosph

172 ovides a signal to promote the expression of lipogenic genes, and the generation of microbial acetate

173 acid oxidation, and decreases expression of lipogenic genes, causing increased plasma HDL and decrea

174 f) livers showed hepatomegaly, activation of lipogenic genes, exacerbated steatosis and liver injury,

175 xpression of SREBP1, the master regulator of lipogenic genes, in MCF10A significantly enhanced lipoge

176 eatment suppresses the expression of several lipogenic genes, including ACLY, MIG12, FASN and NR1D1,

177 E2F1 directly binds to the promoters of key lipogenic genes, including Fasn, but does not bind direc

178 stem that promotes the hepatic expression of lipogenic genes, including stearoyl-CoA desaturase-1 (SC

179 f SHP via phosphorylation recruits DNMT3A to lipogenic genes, leading to epigenetic repression via DN

180 oss of Nrf2 resulted in greater induction of lipogenic genes, lower expression of beta-oxidation gene

181 transcriptional activator of glycolytic and lipogenic genes, plays a central role in this paradox.

182 As the key transcriptional activators of lipogenic genes, such as fatty acid synthase (FAS), ster

183 Significantly high levels of lipogenic genes, such as sterol regulatory element-bindi

184 id synthesis through increased expression of lipogenic genes, thereby contributing to hepatic steatos

185 gnaling pathway leads to intron retention of lipogenic genes, which triggers nonsense-mediated mRNA d

186 uced equivalent, non-additive effects on the lipogenic genes.

187 y regulates expression of key glycolytic and lipogenic genes.

188 ase (FAS) activity and hepatic expression of lipogenic genes.

189 rimethylation (H3K4me3) with the promoter of lipogenic genes.

190 EBP processing, and subsequent expression of lipogenic genes.

191 uced hepatic expression of gluconeogenic and lipogenic genes.

192 d fish showed activation of inflammatory and lipogenic genes.

193 0.05) and a 2-3-fold increased expression of lipogenic genes.

194 mice and reduced the expression of numerous lipogenic genes.

195 remodel chromatin structure and to activate lipogenic genes.

196 cumulation; and (4) diminished expression of lipogenic genes.

197 er the nucleus to transcriptionally activate lipogenic genes.

198 ad reduced rosiglitazone-induced activity at lipogenic genes.

199 eased mRNA and protein expression of several lipogenic genes.

200 and transmitted for epigenetic regulation of lipogenic genes.

201 responses in gene expression, especially in lipogenic genes.

202 to the nucleus to up-regulate expression of lipogenic genes.

203 tent fat accumulation via hypomethylation of lipogenic genes.

204 c, as excessive activation of aPKC-dependent lipogenic, gluconeogenic and proinflammatory pathways in

205 sponse element-binding protein (ChREBP) is a lipogenic glucose-sensing transcription factor with unkn

206 teatohepatitis (NASH) when challenged with a lipogenic, high-fat, high-sucrose diet.

207 Neither the lipogenic index (16:0/18:2n-6) nor the SCD index (16:1n-

208 Lipogenesis was assessed with the lipogenic index and compound specific isotope analysis (

209 0, whereas EPA supplementation increased the lipogenic index by 11% (P < 0.01) and delta13C-16:0 (P =

210 DHA supplementation did not change the lipogenic index or delta13C-16:0, whereas EPA supplement

211 We examined levels of liver fat, lipogenic indices, markers of inflammation, serum levels

212 elated with down-regulation of lipolysis and lipogenic indices.

213 This lipogenic induction involves coordinate transcriptional

214 This lipogenic induction involves coordinate transcriptional

215 o a heart failure phenotype in an adult-like lipogenic milieu.

216 t phosphorylation of glycogenic GSK3beta and lipogenic mTOR was elevated.

217 metabolic profile analysis, we identified a lipogenic network that involves SCD and palmitate signal

218 of SIRT1 and SIRT1-regulated genes encoding lipogenic or fatty acid oxidation enzymes.

219 e time-controlled labeling and monitoring of lipogenic or myogenic populations of lung fibroblasts du

220 de accumulation through an inhibition of the lipogenic pathway but also led, unexpectedly, to hypothe

221 ty-acid synthase, three key functions in the lipogenic pathway in Atf4(-/-) mice.

222 yclin C (CycC) as negative regulators of the lipogenic pathway in Drosophila, mammalian hepatocytes,

223 Our study also documents decreased lipogenic pathway in mesenteric adipose tissue after HFD

224 Together, these results identify a key lipogenic pathway in SMCs that mediates vascular calcifi

225 re we identify a PPARdelta-dependent de novo lipogenic pathway in the liver that modulates fat use by

226 sis is a hallmark of cancer and blocking the lipogenic pathway is known to cause tumor cell death by

227 he regulation of the enzymes involved in the lipogenic pathway under Western HFHC dietary and de novo

228 ivity for the HCV genotype 2a- or 3a-induced lipogenic pathway, exhibiting higher triglyceride synthe

229 scriptional activation of various enzymes in lipogenic pathway, including fatty acid synthase and gly

230 k immunological signals from TCR and IL-2 to lipogenic pathways and functional fitness, and highlight

231 Harnessing lipogenic pathways and rewiring acyl-CoA and acyl-ACP (a

232 levels of lipids and glucose, but continued lipogenic pathways and robust extracellular signal-regul

233 r to mediate these changes via lipolytic and lipogenic pathways in adipose tissue.

234 Activation of these lipogenic pathways is linked to increased de novo lipid

235 tic immune system and development of de novo lipogenic pathways that persist in vitro and may be an i

236 hways that become insulin-resistant but also lipogenic pathways that remain insulin-responsive, as we

237 rized by downregulation of Akt signaling and lipogenic pathways.

238 AMPK to control body fat mass and drive the lipogenic phenotype and growth of melanomas independentl

239 Since a remarkable lipogenic phenotype characterizes liver lesions from AKT

240 while silencing hepatic Osbpl3 reverses the lipogenic phenotype of LRH-1 K289R mice.

241 l mouse model that demonstrates directly how lipogenic phenotypes commonly associated with diet-induc

242 nd the generation of microbial acetate feeds lipogenic pools of acetyl-CoA.

243 This study proposed to investigate the anti-lipogenic potential of a newly developed citrus flavonoi

244 s from nitrogen starvation and unleashed the lipogenic potential of Y. lipolytica Taken together, the

245 TDAG51(-/-) preadipocytes exhibited greater lipogenic potential.

246 tein binding to U1-70K to induce splicing of lipogenic pre-mRNAs.

247 expression of thermogenic genes, the de novo lipogenic program and the lipases ATGL and HSL.

248 findings indicate that rexinoids activate a lipogenic program in mammary epithelial cells through a

249 s role in metabolic adaption to activate the lipogenic program in response to feeding and insulin.

250 in metabolic adaption for activation of the lipogenic program in response to feeding/insulin, and it

251 y element-binding protein (SREBP)-1-mediated lipogenic program.

252 ndings indicate that miR-29 controls hepatic lipogenic programs, likely in part through regulation of

253 ct interaction with USF-1 for recruitment to lipogenic promoter regions.

254 lent to glucose, fructose appears to be more lipogenic, promoting dyslipidemia, fatty liver disease,

255 ich leads us to conclude that XBP1s has anti-lipogenic properties in the liver.

256 postabsorptive humans and whether adipocyte lipogenic proteins (CD36, acyl-CoA synthetases, and diac

257 element-binding protein 1 and key downstream lipogenic proteins and enzymes in fatty acid synthesis w

258 d expression of genes encoding lipolytic and lipogenic proteins.

259 pproximately 50%, due to a decrease in basal lipogenic rate and increase in basal lipolytic rate.

260 owed strong sensitivity to variations in the lipogenic rate constants.

261 ve-element-binding protein (ChREBP, a master lipogenic regulator), and fatty acid synthase (FASN), it

262 Hcy) induced T cell intracellular glycolytic-lipogenic reprogramming and IFN-gamma secretion via pyru

263 This lipogenic response is unique, and is not duplicated by h

264 causes overactivation of the SREBP-dependent lipogenic response to feeding, exacerbating diet-induced

265 nuclear SREBP-1c abundance, and blunted the lipogenic response to feeding, LXR agonist treatment, or

266 ian clock components anticipatorily regulate lipogenic responses to feeding.

267 ride and DAG content, supporting a potential lipogenic role of PNPLA3 in humans.

268 of TAG storage in LDs LDAH plays a primarily lipogenic role, inducing LD growth and enhancing degrada

269 ereas the other two subtypes (glycolytic and lipogenic) showed distinct metabolite levels associated

270 TA exhibited dual effects by inhibiting lipogenic signaling and suppression of lipid metabolic p

271 as biohydrogenation intermediate responsive lipogenic signaling pathway for ruminants and rodents.

272 ls respond by secreting antioxidants and the lipogenic signaling protein Acb1.

273 the activation of IKK-alpha and a cascade of lipogenic signaling to facilitate lipid droplet biogenes

274 epatic steatosis through attenuating hepatic lipogenic signaling.

275 2 diabetes, and cancer require a Fasn-driven lipogenic state, we propose that eIF6 could be a therape

276 epatic TG storage is promoted in response to lipogenic stimulation.

277 In PDAC clinical samples, the lipogenic subtype associated with the epithelial (classi

278 The glycolytic and lipogenic subtypes showed striking differences in glucos

279 Conversely, we observed a myogenic-to-lipogenic switch during fibrosis resolution.

280 he activation of SREBP-1c and its downstream lipogenic target enzymes.

281 eas phenotype, whereas suppressing dSREBP or lipogenic target gene function in eas hearts rescues the

282 ding protein (ChREBP) and its glycolytic and lipogenic target genes was abnormally elevated.

283 (LXRalpha) with increased expression of its lipogenic targets Srebp1c, Chrebp, Lpk, Dgat, Fasn and S

284 s transcriptional targets both in cancer and lipogenic tissue.

285 Our data demonstrate a lipogenic-to-myogenic switch in fibroblastic phenotype d

286 Collectively, our study identifies a basic lipogenic transactivation event with broad relevance to

287 SREBP1c is a key lipogenic transcription factor activated by insulin in t

288 c deacetylase sirtuin 1 (Sirt1) and the anti-lipogenic transcription factor aryl hydrocarbon receptor

289 se tissue (WAT) to control expression of the lipogenic transcription factor ChREBPbeta.

290 encoding gene is a direct target of a major lipogenic transcription factor liver X receptor (LXR)alp

291 umulation by promoting the activation of the lipogenic transcription factor SREBP and by controlling

292 mechanism(s) responsible, we focused on the lipogenic transcription factor SREBP1.

293 ted receptor gamma 2 (PPAR-gamma2), a potent lipogenic transcription factor, in the SHP(-/-) liver.

294 at reduces ER stress, has been proposed as a lipogenic transcription factor.

295 aused the modulation of a complex network of lipogenic transcription factors and enzymes, including S

296 o displayed a reduction in the expression of lipogenic transcription factors, especially sterol-regul

297 es with the expression of genes regulated by lipogenic transcription factors, most prominently liver

298 lipogenic gene transcription, various known lipogenic transcription factors, such as USF1, ChREBP, a

299 By contrast, the lipogenic transcriptional program is activated in respon

300 cytes can efficiently model development of a lipogenic tumor phenotype.